This 3-year Phase II SBIR Application focuses on advancing the lead ?ultra-broad-spectrum? carbapenem (USBC) VNRX-4099, possessing an unprecedented antibacterial spectrum of activity including MRSA, Enterobacteriaceae and Pseudomonas aeruginosa, to IND filing status. The UBSC VNRX-4099 will be paired with a proprietary in-house ?-lactamase inhibitor VNRX-5133 (BLI) to protect against resistance by Ambler Class A, B and D carbapenemase-producing Gram negatives. In parallel, a discovery effort will be executed to identify a fast follower and/or chemically-diverse back-up UBSC that could be advanced into IND-enabling studies if required. Ultimately, it is envisioned that this new combination product will provide a unique clinical option for empiric therapy of multi-drug resistant polymicrobial infections in the hospital general ward and ICU, and as a second line therapy for susceptible organisms.
We are developing a Preclinical Candidate from a new class of ultra-broad spectrum carbapenems with activity that extends to MRSA, Enterobacteriaceae and Pseudomonas aeruginosa. The compound will be paired with a proprietary ?-lactamase inhibitor with activity that extends to all Ambler classes of carbapenemases. This combination promises to be a powerful new single-treatment option against problematic, multi-drug resistant pathogens.
